Fjarde Ap Fonden Seagen Inc. Transaction History

Fjarde Ap Fonden

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 23, 2023	SELL	$191.51 - $216.16 $268,114 - $302,624	-1,400 Reduced 2.84%	47,859 $10.2 Million
Q2 2023 Aug 02, 2023	BUY	$187.64 - $206.25 $431,571 - $474,375	2,300 Added 4.9%	49,259 $9.48 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $867,612 - $1.38 Million	6,800 Added 16.93%	46,959 $9.51 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $1.48 Million - $1.76 Million	-12,617 Reduced 23.91%	40,159 $5.16 Million
Q2 2022 Aug 11, 2022	BUY	$108.81 - $179.33 $946,647 - $1.56 Million	8,700 Added 19.74%	52,776 $9.34 Million
Q1 2022 May 13, 2022	SELL	$119.61 - $157.85 $155,493 - $205,205	-1,300 Reduced 2.86%	44,076 $6.35 Million
Q4 2021 Feb 15, 2022	BUY	$142.57 - $190.86 $213,855 - $286,290	1,500 Added 3.42%	45,376 $7.02 Million
Q3 2021 Nov 15, 2021	BUY	$142.45 - $169.82 $14,244 - $16,982	100 Added 0.23%	43,876 $7.45 Million
Q2 2021 Aug 12, 2021	SELL	$135.08 - $161.1 $243,144 - $289,980	-1,800 Reduced 3.95%	43,776 $6.91 Million
Q1 2021 May 17, 2021	BUY	$137.51 - $190.8 $330,024 - $457,920	2,400 Added 5.56%	45,576 $6.33 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $7.11 Million - $9.15 Million	43,176 New	43,176 $7.56 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Fjarde Ap Fonden , based on Form 13F filings with the SEC.

Stay updated on Fjarde Ap Fonden with notifications on news.